Terms: = Sarcomas AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
425 results:
1. Drugging the undruggable: Advances in targeting kras signaling in solid tumors.
Tripathi P; Kumari R; Pathak R
Int Rev Cell Mol Biol; 2024; 385():1-39. PubMed ID: 38663957
[TBL] [Abstract] [Full Text] [Related]
2. Temporal trends and regional variability in BRAF and kras genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
3. Decoding the Versatile Landscape of Autophagic Protein VMP1 in Cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
4. SG-Transunet: A segmentation-guided Transformer U-Net model for kras gene mutation status identification in colorectal cancer.
Ma Y; Guo Y; Cui W; Liu J; Li Y; Wang Y; Qiang Y
Comput Biol Med; 2024 May; 173():108293. PubMed ID: 38574528
[TBL] [Abstract] [Full Text] [Related]
5. Management of
Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB
Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474
[TBL] [Abstract] [Full Text] [Related]
6. Cascade Co
Wang L; Wang T; Zhuo Y; Xu S; Liu H; Jiang X; Lu Z; Wang X; Rao H; Wu D; Wang Y; Feng B; Sun M
J Colloid Interface Sci; 2024 May; 662():962-975. PubMed ID: 38382379
[TBL] [Abstract] [Full Text] [Related]
7. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
[TBL] [Abstract] [Full Text] [Related]
8. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
[TBL] [Abstract] [Full Text] [Related]
9. The association between kras and histopathological growth patterns and the impact on resection margins around vasculature and bile ducts in colorectal liver metastases.
Wong P; Wong GYM; Toon CW; Chapuis P; Hugh TJ
ANZ J Surg; 2024 Apr; 94(4):560-565. PubMed ID: 38366706
[TBL] [Abstract] [Full Text] [Related]
10. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
[TBL] [Abstract] [Full Text] [Related]
11. Application of plasma circulating kras mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract] [Full Text] [Related]
12. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract] [Full Text] [Related]
13. Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in kras
Lin P; Cheng W; Qi X; Zhang P; Xiong J; Li J
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338834
[TBL] [Abstract] [Full Text] [Related]
14. Histiocytic sarcoma following CAR T-cell therapy: a case report.
An K; He Y; Tang Y; Gu X; Qian J; Li B
Int J Hematol; 2024 Mar; 119(3):338-341. PubMed ID: 38294639
[TBL] [Abstract] [Full Text] [Related]
15. A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
Latimer NR; Dewdney A; Campioni M
BMC Med Res Methodol; 2024 Jan; 24(1):17. PubMed ID: 38253996
[TBL] [Abstract] [Full Text] [Related]
16. A novel method for detection of pancreatic Ductal Adenocarcinoma using explainable machine learning.
Aslam M; Rajbdad F; Azmat S; Li Z; Boudreaux JP; Thiagarajan R; Yao S; Xu J
Comput Methods Programs Biomed; 2024 Mar; 245():108019. PubMed ID: 38237450
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
18. Sotorasib with panitumumab in chemotherapy-refractory kras
Kuboki Y; Fakih M; Strickler J; Yaeger R; Masuishi T; Kim EJ; Bestvina CM; Kopetz S; Falchook GS; Langer C; Krauss J; Puri S; Cardona P; Chan E; Varrieur T; Mukundan L; Anderson A; Tran Q; Hong DS
Nat Med; 2024 Jan; 30(1):265-270. PubMed ID: 38177853
[TBL] [Abstract] [Full Text] [Related]
19. Mass spectrometry analysis of intact protein
Xu M; Liu Z; Hu W; Han Y; Wu Z; Chen S; Xia P; DU J; Zhang X; Hao P; Xia J; Yang S
J Zhejiang Univ Sci B; 2024 Jan; 25(1):51-64. PubMed ID: 38163666
[TBL] [Abstract] [Full Text] [Related]
20. NLRP3 inflammasome activation and symptom burden in kras-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L; Cuenca-Zamora EJ; Zamora L; Bellosillo B; Such E; Soler-Espejo E; Martínez-Banaclocha H; Hernández-Rivas JM; Marco-Ayala J; Martínez-Alarcón L; Linares-Latorre L; García-Ávila S; Amat-Martínez P; González T; Arnan M; Pomares-Marín H; Carreño-Tarragona G; Chen-Liang TH; Herranz MT; García-Palenciano C; Morales ML; Jerez A; Lozano ML; Teruel-Montoya R; Pelegrín P; Ferrer-Marín F
Cell Rep Med; 2023 Dec; 4(12):101329. PubMed ID: 38118408
[TBL] [Abstract] [Full Text] [Related]
[Next]
